We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

$XFOR ($XFOR) is expected to release its quarterly earnings data on Tuesday, March 25th before market open, per Finnhub. Analysts are expecting revenue of $1,061,820 ...

Shares of XFOR stock opened at $0.31 on Friday. The stock has a market capitalization of $52.41 million, a P/E ratio of -3.41 and a beta of 0.39. The company has a current ratio of 4.89 ...

The latest price target for X4 Pharmaceuticals (NASDAQ:XFOR) was reported by HC Wainwright & Co. on March 27, 2025. The analyst firm set a price target for $1.50 expecting XFOR to rise to within ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

X4 Pharmaceuticals Inc (NASDAQ:XFOR) achieved US approval and launched its first product, XOLREMDI, for WHIM syndrome in 2024. The company has established strong partnerships with Norgine and ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and Sanara MedTech (SMTI – Research Report ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is currently evaluating mavorixafor in a Phase 3 clinical trial in chronic neutropenia (CN) patients. The 4WARD trial is expected to enroll a total of 150 ...